Access Investment Management LLC Raises Stake in United Therapeutics Co. (NASDAQ:UTHR)

Access Investment Management LLC increased its stake in shares of United Therapeutics Co. (NASDAQ:UTHR) by 0.8% during the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 7,335 shares of the biotechnology company’s stock after purchasing an additional 55 shares during the period. Access Investment Management LLC’s holdings in United Therapeutics were worth $2,588,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in the stock. Hussman Strategic Advisors Inc. lifted its holdings in United Therapeutics by 33.3% during the 4th quarter. Hussman Strategic Advisors Inc. now owns 8,400 shares of the biotechnology company’s stock worth $2,964,000 after purchasing an additional 2,100 shares in the last quarter. Ieq Capital LLC boosted its position in shares of United Therapeutics by 307.6% during the 4th quarter. Ieq Capital LLC now owns 6,852 shares of the biotechnology company’s stock valued at $2,418,000 after acquiring an additional 5,171 shares during the last quarter. Global Retirement Partners LLC boosted its position in shares of United Therapeutics by 38.0% during the 4th quarter. Global Retirement Partners LLC now owns 596 shares of the biotechnology company’s stock valued at $210,000 after acquiring an additional 164 shares during the last quarter. Cardinal Capital Management boosted its position in shares of United Therapeutics by 1.9% during the 4th quarter. Cardinal Capital Management now owns 11,068 shares of the biotechnology company’s stock valued at $3,905,000 after acquiring an additional 208 shares during the last quarter. Finally, Kestra Investment Management LLC bought a new stake in shares of United Therapeutics during the 4th quarter valued at about $603,000. Hedge funds and other institutional investors own 94.08% of the company’s stock.

United Therapeutics Price Performance

Shares of United Therapeutics stock opened at $361.10 on Friday. The business’s 50 day simple moving average is $362.68 and its two-hundred day simple moving average is $360.45. The stock has a market capitalization of $16.12 billion, a P/E ratio of 15.86, a price-to-earnings-growth ratio of 0.97 and a beta of 0.57. United Therapeutics Co. has a one year low of $214.75 and a one year high of $417.82.

Insiders Place Their Bets

In other news, COO Michael Benkowitz sold 10,000 shares of the business’s stock in a transaction that occurred on Monday, November 25th. The stock was sold at an average price of $372.75, for a total transaction of $3,727,500.00. Following the transaction, the chief operating officer now directly owns 2,577 shares of the company’s stock, valued at approximately $960,576.75. The trade was a 79.51 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Paul A. Mahon sold 7,700 shares of the business’s stock in a transaction that occurred on Thursday, December 5th. The shares were sold at an average price of $374.37, for a total value of $2,882,649.00. Following the transaction, the executive vice president now directly owns 36,710 shares in the company, valued at $13,743,122.70. This trade represents a 17.34 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 124,164 shares of company stock valued at $45,398,793 in the last ninety days. Company insiders own 11.90% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on the company. Oppenheimer lifted their price target on United Therapeutics from $575.00 to $600.00 and gave the company an “outperform” rating in a research report on Thursday, October 31st. HC Wainwright lifted their price target on United Therapeutics from $400.00 to $425.00 and gave the company a “buy” rating in a research report on Thursday, October 31st. The Goldman Sachs Group boosted their target price on United Therapeutics from $243.00 to $302.00 and gave the stock a “neutral” rating in a research report on Friday, November 1st. UBS Group boosted their target price on United Therapeutics from $415.00 to $475.00 and gave the stock a “buy” rating in a research report on Wednesday, January 8th. Finally, StockNews.com upgraded United Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Thursday, January 16th. One research analyst has rated the stock with a sell rating, two have issued a hold rating, nine have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $388.25.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.